December 14, 2016 / 1:18 PM / in 9 months

BRIEF-Redhill Biopharma and Intelgenx enters into an agreement for commercialization of Rizaport

Dec 14 (Reuters) - Redhill Biopharma Ltd -

* Redhill, Intelgenx expect to re-submit Rizaport U.S. New drug application to FDA in H1 2017, subsequently receive a new PDUFA date

* Redhill Biopharma and Intelgenx announce definitive agreement for commercialization of Rizaport for migraines with Pharmatronic co. in south korea Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below